WO2004093829A8 - (-)1-(4-sulfamylaryl)-3-substituted-5-heteroaryl-2 pyrazolines as inhibitors of cyclooxygenase-2 - Google Patents

(-)1-(4-sulfamylaryl)-3-substituted-5-heteroaryl-2 pyrazolines as inhibitors of cyclooxygenase-2

Info

Publication number
WO2004093829A8
WO2004093829A8 PCT/US2004/008358 US2004008358W WO2004093829A8 WO 2004093829 A8 WO2004093829 A8 WO 2004093829A8 US 2004008358 W US2004008358 W US 2004008358W WO 2004093829 A8 WO2004093829 A8 WO 2004093829A8
Authority
WO
WIPO (PCT)
Prior art keywords
cyclooxygenase
inhibitors
sulfamylaryl
pyrazolines
heteroaryl
Prior art date
Application number
PCT/US2004/008358
Other languages
French (fr)
Other versions
WO2004093829A2 (en
WO2004093829A3 (en
Inventor
Premkumar E Reddy
Ramana M V Reddy
Stanley C Bell
Original Assignee
Univ Temple
Onconova Therapeutics Inc
Premkumar E Reddy
Ramana M V Reddy
Stanley C Bell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Onconova Therapeutics Inc, Premkumar E Reddy, Ramana M V Reddy, Stanley C Bell filed Critical Univ Temple
Publication of WO2004093829A2 publication Critical patent/WO2004093829A2/en
Publication of WO2004093829A3 publication Critical patent/WO2004093829A3/en
Publication of WO2004093829A8 publication Critical patent/WO2004093829A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The (-)-enantiomers of the optically active compounds of the formula (I) wherein X, Z and R5 are as defined herein, and pharmaceutically acceptable salts thereof, are inhibitors of cyclooxygenase-2 activity. The compounds are useful for treating cyclooxygenase-mediated disorders, including, for example, inflammation, neoplastic disorders and angiogenesis-mediated disorders.
PCT/US2004/008358 2003-03-31 2004-03-19 (-)1-(4-sulfamylaryl)-3-substituted-5-heteroaryl-2 pyrazolines as inhibitors of cyclooxygenase-2 WO2004093829A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45941503P 2003-03-31 2003-03-31
US60/459,415 2003-03-31

Publications (3)

Publication Number Publication Date
WO2004093829A2 WO2004093829A2 (en) 2004-11-04
WO2004093829A3 WO2004093829A3 (en) 2005-02-17
WO2004093829A8 true WO2004093829A8 (en) 2005-05-12

Family

ID=33310704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/008358 WO2004093829A2 (en) 2003-03-31 2004-03-19 (-)1-(4-sulfamylaryl)-3-substituted-5-heteroaryl-2 pyrazolines as inhibitors of cyclooxygenase-2

Country Status (1)

Country Link
WO (1) WO2004093829A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361748T1 (en) * 1999-06-16 2007-06-15 Univ Temple 1-(4-SULFAMYLPHENYL)-3-TRIFLUORMETHYL-5-ARYL-2-PYRAZOLINE AS CYCLOOXYGENASE-2 INHIBITORS

Also Published As

Publication number Publication date
WO2004093829A2 (en) 2004-11-04
WO2004093829A3 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
ZA200700481B (en) N-(1-(1-beznyl-4-pheynl-1H-imidazol-2-yl)-2,2-dymenthylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
YU5503A (en) Non-steroidal inflammation inhibitors
DK1318992T3 (en) Imidazole derivatives as Raf kinase inhibitors
RS17004A (en) Alkyne-aryl phosphodiesterase-4 inhibitors
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2006066133A3 (en) Histone deacetylase inhibitors
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2011053938A8 (en) Methods and compositions for treating cancer
ATE324371T1 (en) N-SUBSTITUTED HETEROCYCLIC NONARYL NMDA/NR2B ANTAGONISTS
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
BRPI0412999A (en) Substituted 2-aminotetraline for depression treatment
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
PA8592101A1 (en) NEW ENANTIOMERS (R) AND (S) OF HYDROXAMIC THIOPHEN ACID DERIVATIVES
NO20081888L (en) Triazole Compounds as Lipoxygenase Inhibitors
MX2010002938A (en) (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1- carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating.
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
MXPA05010521A (en) Biphenyl carboxylic amide p38 kinase inhibitors.
ATE359283T1 (en) SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION
WO2006110173A3 (en) Novel compounds
PL373085A1 (en) Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
122 Ep: pct application non-entry in european phase